Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intranasal challenge drug · 1 trial · 1 indication
The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.
| Arm | Type | Description |
|---|---|---|
| Bup 8 | EXPERIMENTAL | Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally. |
| Bup 16 | EXPERIMENTAL | Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally. |
| Bup/Nal 8/2 | EXPERIMENTAL | Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone. |
| Bup/Nal 8/8 | EXPERIMENTAL | Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone. |
| Bup/Nal 8/16 | EXPERIMENTAL | Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone. |
| Bup/Nal 16/4 | EXPERIMENTAL | Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone. |
| Heroin | ACTIVE_COMPARATOR | Intranasal challenge drug: 24 mg of heroin administered intranasally. |
| Placebo | SHAM_COMPARATOR | Intranasal challenge drug: Intranasal lactose powder. |
| Naloxone 4 mg | ACTIVE_COMPARATOR | Intranasal challenge drug: Intranasal Naloxone 4mg. |
| Name | Type | Description |
|---|---|---|
| Intranasal challenge drug | DRUG | Each of the experimental challenge drugs were administered intranasally to all participants in random order. |
Inclusion Criteria: * DSM IV criteria for heroin dependence * No major mood, psychotic, or anxiety disorder * Physically healthy * Able to perform study procedures * 21-45 years of age * Normal body weight * Current use of opioids in amounts and/or frequencies that meet or exceed those used in the ...
Intranasal challenge drug is an investigational small molecule being studied for the treatment of heroin dependence. It is being developed by Indivior Pharmaceuticals, Inc. (INDV) and is currently in Phase 3 clinical development. The drug is administered intranasally and is being evaluated in a clinical trial setting.
The specific molecular target of Intranasal challenge drug is not disclosed in the available information. The drug is being studied for its effects on heroin dependence, but the precise mechanism of action has not been specified. It is a small molecule modality developed by Indivior Pharmaceuticals, Inc.
Intranasal challenge drug is being developed by Indivior Pharmaceuticals, Inc., a company listed on the stock exchange under the ticker symbol INDV. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with heroin dependence.
Intranasal challenge drug is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of heroin dependence, and its clinical trial program includes a completed Phase 3 study.
Intranasal challenge drug has one completed clinical trial, identified by the National Clinical Trial number NCT01760473. This Phase 3 study, titled 'Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,' enrolled 27 participants with heroin dependence in the United States. The trial was randomized, double-blind, and active-controlled.
Intranasal challenge drug is being studied in comparison to buprenorphine and buprenorphine/naloxone in a clinical trial. The trial title suggests the drug may be related to buprenorphine, but the specific identity of Intranasal challenge drug is not explicitly stated. It is an investigational drug developed by Indivior Pharmaceuticals.